Meet Me et the he De Deleg egates ates ! Karl Gumpper (year 4) - PowerPoint PPT Presentation

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Meet Me et the he De Deleg egates ates ! • Karl Gumpper (year 4) • Erin Taylor (year 3) • Caryn Belisle (year 2) • Jackie Maccormack-Gagnon (year 1) • Bryan Wood (alternate, 1-year term)

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Objec Ob ectives tives • Describe the process of ASHP professional policy development • Identify 3 ASHP professional policies that will be reviewed at the 2019 Annual Session of the House of Delegates • Discuss the perspectives of MSHP members on the issues presented

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Policy Po cy De Develo elopment pment • What is a professional policy? • ASHP’s official stance on an issue related to pharmacy practice or the use of medications in society • Focuses on the right thing to do • Serves to improve patient care and advance practice • Based on analysis and evidence • Importance: • Helps develop and define pharmacy practice • Provides direction to staff from members • Provides direction for resource allocation • Defines uniqueness of ASHP • Serves as an authority for advocacy Adopted from ASHP Policy Process Overview Slide deck – April 2018 (Bruce Hawkins)

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Policy Po cy De Develo elopment pment • Six types of ASHP Policy • These ARE intended to be: • Policy Position • VOLUNTARY • Policy Statement • FORWARD-LOOKING • Practice Guidelines • These are NOT intended to • Therapeutic Guidelines be: • Therapeutic Position Statement • Law • Endorsed Document • Regulation

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Policy Po cy Cy Cycle le Sources for Policy Development/Initiat January September Board of ion : Policy Week Directors • HOD Meeting Recommendations Late June February • HOD Resolutions Councils Councils Meet Meet • ASHP Surveys • Member suggestions to June March Standards Mailbox House of Delegates Virtual • ASHP House of Board of Directors Delegates Meeting Sections/Forums May April • ASHP Councils Regional Board of • ASHP Commissions Delegate Directors Conferences Meeting

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: AS ASHP HP Pr Prof ofes essional sional Po Policy cy Ini nitiatio tiation • COUNCILS/COMMISSIONS: Create, Draft and Recommend to Board of Directors • Council on Education and Workforce Development (Nicole Clark – MA/Chair) • Council on Pharmacy Management • Council on Pharmacy Practice • Council on Public Policy (Chris Fortier – MA/Vice Chair, Melissa Ortega – MA) • Council on Therapeutics (Snehal Bhatt – MA/Vice Chair) • SECTIONS AND FORUMS: • Section of Ambulatory Care Practitioners • Section of Clinical Specialists and Scientists • Section of Inpatient Care Practitioners • Section of Pharmacy Informatics & Technology • Section of Pharmacy Practice Managers • New Practitioners Forum • Pharmacy Students Forum • Pharmacy Technician Forum

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Review Re ew Pr Proc oces ess s for or Ne New w Po Policy cy Board of Directors: House of Delegates: (led by the Chair of • Reviews the HOD) • Amends • Review (w/input from • Recommends policy constituents) positions and statements to House • Amend (w/input from of Delegates for constituents) approval • Approve • Approves guidelines, therapeutic position statements, and endorsed documents

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: ASHP AS HP Po Policy cy Po Position tions s an and d Gu Guide delines lines Where can you find them? www.ashp.org/Pharmacy-Practice/Policy-Positions-and- Guidelines

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Po Policies cies for or Di Discussion cussion • Pharmacy Expertise in Sterile Compounding • Therapeutic Use of Cannabidiol • Preventing Drug Product Shortages

ASHP AS HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Phar Ph arma macy cy Ex Expe pertis rtise e in St n Ster erile ile Comp Co mpou oundin nding To support colleges of pharmacy in providing sterile compounding and aseptic technique instruction in didactic and experiential curricula that reflect the needs of the workforce; further, To promote the use of sterile compounding training programs to foster an increase in the number of pharmacists and pharmacy technicians with sterile compounding expertise; further, To advocate that pharmacists and pharmacy technicians who work in sterile compounding attain compounded sterile preparations advanced certifications.

AS ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Ph Phar arma macy cy Ex Expe pertis rtise e in St n Ster erile ile Comp Co mpou oundin nding Let’s Discuss! • What do you think? • Any recommendations we should bring back?

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Self-Assess Se Assessment ment Qu Ques estio tion n #1 #1 Which of the following is/are correct regarding the ASHP proposed policy for “Pharmacy Expertise in Sterile Compounding”? A. To support colleges of pharmacy in providing sterile compounding and aseptic technique instruction in didactic and experiential curricula that reflect the needs of the workforce. B. To promote the use of sterile compounding training programs to foster an increase in the number of pharmacists and pharmacy technicians with sterile compounding expertise. C. To advocate that pharmacists and pharmacy technicians who work in sterile compounding attain compounded sterile preparations advanced certifications. D. A & C only E. A, B, and C

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Self-Assess Se Assessment ment Qu Ques estio tion n #1 #1 Which of the following is/are correct regarding the ASHP proposed policy for “Pharmacy Expertise in Sterile Compounding”? A. To support colleges of pharmacy in providing sterile compounding and aseptic technique instruction in didactic and experiential curricula that reflect the needs of the workforce. B. To promote the use of sterile compounding training programs to foster an increase in the number of pharmacists and pharmacy technicians with sterile compounding expertise. C. To advocate that pharmacists and pharmacy technicians who work in sterile compounding attain compounded sterile preparations advanced certifications. D. A & C only E. A, B, and C

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Th Ther erap apeut eutic ic Us Use e of of Ca Cann nnab abidiol idiol To support continued research on the therapeutic uses of cannabidiol (CBD); further, To provide education on the therapeutic uses of CBD; further, To oppose use of CBD-containing products not approved by the Food and Drug Administration; further, To advocate for enhanced public education regarding safe use of CBD and unapproved CBD-containing products. To recommend health systems develop policies to address patient care needs when a patient presents taking CBD- containing products.

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Ther Th erap apeut eutic ic Us Use e of of Ca Cann nnab abidiol idiol Let’s Discuss! • What do you think? • Any recommendations we should bring back?

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Se Self-Assess Assessment ment Qu Ques estio tion n #2 #2 Which of the following is false regarding the ASHP proposed policy for “Therapeutic Use of Cannabidiol (CBD)”? A. To provide education on the therapeutic uses of CBD. B. To oppose use of all CBD-containing products. C. To advocate for enhanced public education regarding safe use of CBD and unapproved CBD-containing products. D. To support continued research on the therapeutic uses of CDB.

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Se Self-Assess Assessment ment Qu Ques estio tion n #2 #2 Which of the following is false regarding the ASHP proposed policy for “Therapeutic Use of Cannabidiol (CBD)”? A. To provide education on the therapeutic uses of CBD. B. To oppose use of all CBD-containing products. C. To advocate for enhanced public education regarding safe use of CBD and unapproved CBD-containing products. D. To support continued research on the therapeutic uses of CDB.